The association between RASSF1A promoter methylation and prostate cancer: Evidence from 19 published studies

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3881-3890

  Ge, Yu Zheng ^a   Xu, Lu Wei ^a   Jia, Rui Peng ^a   Xu, Zheng ^a   Feng, Yu Ming ^a   Wu, Ran ^a   Yu, Peng ^a   Zhao, Yan ^a   Gui, Zan Long ^a   Tan, Si Jia ^a   Song, Qun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Meta analysis; Methylation; Prostate cancer; RASSF1A

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ARTICLE; CANCER RISK; CANCER STAGING; GLEASON SCORE; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS (TOPIC); METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PUBLISHING; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; URINALYSIS;

DNA METHYLATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PUBLICATION BIAS; RISK; TUMOR SUPPRESSOR PROTEINS;

EID: 84899126537     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1515-3     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30. doi: 10.3322/caac.21166.
2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156-61. doi: 10.1056/ NEJM199104253241702.
3. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28(1):126-31. doi: 10.1200/JCO.2009.24.2180.
4. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9. doi: 10.1056/NEJMoa0810696.
5. Suva ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;339(6127):1567-70. doi: 10.1126/science.1230184.
6. Bastian PJ, Yegnasubramanian S, Palapattu GS, Rogers CG, Lin X, De Marzo AM, et al. Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur Urol. 2004;46(6):698-708. doi: 10.1016/j.eururo.2004.07. 022.
7. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate. 2012;72(11):1248-61. doi: 10.1002/pros.22459.
8. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol. 2011;60(4):753-66. doi: 10.1016/j.eururo.2011.06.035.
9. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65(9):3497-508. doi: 10.1158/0008-5472.CAN-04-4088.
10. Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers. 2007;23(1-2):73-87.
11. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315-9. doi: 10.1038/77083.
12. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res. 2002;8(2):514-9.
13. Liu L, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene. 2002;21(44):6835-40. doi: 10.1038/sj.onc.1205814.
14. Woodson K, Hanson J, Tangrea J. A survey of gene-specific methylation in human prostate cancer among black and white men. Cancer Lett. 2004;205(2):181-8. doi: 10.1016/j.canlet.2003.11.027.
15. Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease. Oncol Rep. 2004;12(3):631-7.
16. Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, Engers R, et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer. 2004;91(5):985-94. doi: 10.1038/sj.bjc.6602030.
17. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G, et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res. 2004;10(24):8472-8. doi: 10.1158/1078-0432.CCR-04-0894.
18. Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Muller SC, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res. 2005;11(11):4097-106. doi: 10.1158/1078-0432.CCR-04-1832.
19. Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005;23(27):6569-75. doi: 10.1200/JCO.2005.07.009.
20. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM, et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol. 2007;211(3):269-77. doi: 10.1002/path.2106.
21. Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007;13(6):1720-5. doi: 10.1158/1078-0432.CCR-06-2467.
22. Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res. 2007;13(9):2541-8. doi: 10.1158/1078-0432.CCR- 06-2225.
23. Henrique R, Ribeiro FR, Fonseca D, Hoque MO, Carvalho AL, Costa VL, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 2007;13(20):6122-9. doi: 10.1158/1078-0432.CCR-07-1042.
24. Roupret M, Hupertan V, Catto JW, Yates DR, Rehman I, Proctor LM, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer. 2008;122(4):952-6. doi: 10.1002/ijc.23196.
25. Syeed N, Syed Sameer A, Hamid A, Shah ZA, Afroze D, Rasool R, et al. Promoter methylation profile of GSTP1 and RASSF1A in benign hyperplasia and metastatic prostate cancer patients in a Kashmiri population. Mol Med Rep. 2010;3(5):883-7. doi: 10.3892/mmr.2010.348.
26. Liu L, Kron KJ, Pethe VV, Demetrashvili N, Nesbitt ME, Trachtenberg J, et al. Association of tissue promoter methylation levels of APC, TGFbeta2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer. 2011;129(10):2454- 62. doi: 10.1002/ijc.25908.
27. Vasiljevic N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers. 2011;30(4):151-61. doi: 10.3233/DMA-2011-0790.
28. Dimitriadis E, Kalogeropoulos T, Velaeti S, Sotiriou S, Vassiliou E, Fasoulis L, et al. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer. Anticancer Res. 2013;33(1):191-7.
29. Yaqinuddin A, Qureshi SA, Pervez S, Bashir MU, Nazir R, Abbas F. Frequent DNA hypermethylation at the RASSF1A and APC gene loci in prostate cancer patients of Pakistani origin. ISRN Urol. 2013;2013:627249. doi: 10.1155/2013/627249.
30. Divyya S, Naushad SM, Murthy PV, Reddy CR, Kutala VK. GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD. Mol Biol Rep. 2013. doi: 10.1007/s11033-013-2655-7.
31. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64(6):1975-86.
32. Prior C, Guillen-Grima F, Robles JE, Rosell D, Fernandez-Montero JM, Agirre X, et al. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol. 2010;28(6):681-6. doi: 10.1007/s00345-010-0583-x.
33. Padar A, Sathyanarayana UG, Suzuki M, Maruyama R, Hsieh JT, Frenkel EP, et al. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res. 2003;9(13):4730-4.
34. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol. 2004;202(2):233-40. doi: 10.1002/path.1503.
35. Woodson K, Gillespie J, Hanson J, Emmert-Buck M, Phillips JM, Linehan WM, et al. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: a histopathologic study of whole mount prostate specimens. Prostate. 2004;60(1):25-31. doi: 10.1002/pros.20013.
36. Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008;179(2):529-34. doi: 10.1016/j.juro.2007.09.038. discussion 34-5.
37. Pan J, Chen J, Zhang B, Chen X, Huang B, Zhuang J, et al. Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis. PLoS One. 2013;8(9):e75283. doi: 10.1371/journal.pone. 0075283.
38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557.
39. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-48.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
41. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291-306. doi: 10.1002/sim.2010.
42. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088-101.
43. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34.
44. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
45. Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol. 2003;18(2):665-77.
46. Pfeifer GP, Dammann R. Methylation of the tumor suppressor gene RASSF1A in human tumors. Biochemistry (Mosc). 2005;70(5):576-83.
47. Kuzmin I, Gillespie JW, Protopopov A, Geil L, Dreijerink K, Yang Y, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 2002;62(12):3498-502.
48. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429(6990):457-63. doi: 10.1038/nature02625.
49. Gao T, Wang S, He B, Pan Y, Song G, Gu L, et al. The association of RAS association domain family Protein1A (RASSF1A) methylation states and bladder cancer risk: a systematic review and meta-analysis. PLoS One. 2012;7(11):e48300. doi: 10.1371/journal.pone.0048300.
50. Truong M, Yang B, Jarrard DF. Toward the detection of prostate cancer in urine: a critical analysis. J Urol. 2013;189(2):422-9. doi: 10.1016/j.juro.2012. 04.143.
51. Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol. 2010;7(2):101-9. doi: 10.1038/nrurol.2009.261.